PSS59 Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study  by Paul, C et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A425
Objectives: Treatment options continue to emerge for managing psoriasis, with 
different risk:benefit profiles and routes of administration. This study was designed 
to elicit UK patients’ relative strength of preference regarding treatment effectiveness, 
risks of side effects, and mode/frequency of administration. MethOds: A stated 
preference survey (using a discrete choice experiment [DCE]) was designed to present 
participants with hypothetical treatment choices. Treatments were described in terms 
of reducing the body surface area (BSA) affected by psoriasis, mode of administration, 
increase in risk of diarrhea or nausea in the short-term, and 10-year risk of melanoma, 
tuberculosis, or serious infection (e.g., pneumonia). Standard DCE Methodswith an 
orthogonal design were used; the survey was pilot-tested in 6 participants. Results: 
Psoriasis patients (n= 292; mean age= 48.5 years; mean BSA= 9.3%; mean Dermatology 
Life Quality Index= 10.5; 25.7% with prior biologic experience and 34.9% with pso-
riatic arthritis) were recruited in the UK. Participants strongly preferred to avoid 
increasing their risk of melanoma (odds ratio [OR]= 0.44/5% increased 10-year risk), 
tuberculosis, and serious infections (OR= 0.73/5% increased 10-year risk for both) 
and preferred twice-daily tablets to weekly injections (OR= 0.74) or injections every 
2 weeks (OR= 0.86). Participants preferred to avoid treatments with a risk of diarrhea 
or nausea in the first few weeks after initiation (OR= 0.87/5% increase) and preferred 
treatments that effectively resolve plaque lesions (OR= 0.93 for each hand palm area 
still affected). All ORs were statistically significant. Biologic-naïve participants were 
more likely to prefer oral tablets to injections and were less risk-tolerant for serious 
adverse events. cOnclusiOns: All attributes of treatment considered were found 
to be significant predictors of choice. Patients showed strong preferences for avoiding 
treatments with risk of serious toxicities and avoiding injectable therapy, and a lower 
preference for treatments with greater efficacy. These preferences were consistently 
stronger in biologic-naïve patients.
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Objectives: This study is design to assess the dental status and perception towards oral 
health among pharmacy students. MethOds: The study is questionnaire bases cross 
sectional study. Study is conducted in Faculty of Pharmacy, University of Balochistan, 
Quetta by using convenient sampling. The descriptive statistics was used to present 
the demographic and disease related information. Inferential statistics was used to the 
evaluation relationship among study variables. All analyses were performed using SPSS 
20.0. Results: Out of 197 participants 196 (66.0%) were male. Majority of participants 
267 (89.9%) having age ranges between 18-24 years. One hundred ninety one (64.3%) 
describe that they have no problem in chewing and 172 (53.9%) are satisfied with their 
teeth appearance which shows the satisfaction of participants concerning their oral 
dental health. Majority of respondents 120 (40.4%) were satisfied with their teeth. One 
hundred and sixty one (54.2%) respondents were having minor teeth problems. Score for 
self-rating of dental health in majority of participants 121 (40.7%) was excellent. When 
discussing the self-rating score no significance difference was found in participants 
having dental problem, broken filling, broken tooth, cavities, bleeding gums, bad breath, 
stained teeth, aches and broken denture. cOnclusiOns: Present Study concluded that 
although the participant were satisfied with their oral dental health, yet they are not 
aware about the proper hygiene and oral dental health. Awareness program must be 
initiated for students, focusing primarily on dental/oral health.
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Objectives: Acne vulgaris is one of the most common skin conditions, affecting 
primarily the adolescents. The psychological impact associated with the condition 
could be explained by the predominance of lesions in the face. The objective of the 
present study was to describe the characteristics of the disease and its management 
in Europe considering the patients’ perspective. MethOds: A cross-sectional survey 
was conducted in a sample of individuals residing in Europe and aged 15 to 24. To 
ensure representativeness, the quota method was applied considering age, sex, resi-
dence location and occupational status of the reference person. Study participants 
were asked to complete an online questionnaire specifically developed for the study 
and Resultswere analysed descriptively. Results: A total of 3099 study participants 
declared currently having acne. Outside of the face, the back was affected by lesions 
in 61.05% of individuals on average (65.95% of men and 56.22% of women). Most 
patients (27.03%) reported their general physician or dermatologist as the main source 
of information on acne. However, advices were also often sought from relatives and 
internet. In addition, whereas the diagnosis of acne is generally made by a derma-
tologist (29.69%), most patients, reporting acne in our study, declared that no medical 
diagnosis was ever made (39.3%). This can explain why most individuals (28.65%) 
reported using anti-acne cosmetics advised by their pharmacists instead of prescribed 
treatments. Finally, according to patients’ perspective, acne is generally considered a 
minor issue however, for 21.3% of individuals it represents a major problem and 1.9% 
lives it as a real burden. These Resultsare consistent across the selected European 
countries. cOnclusiOns: Acne is a common disease considered a minor issue by 
most adolescent patients and commonly self-managed using anti-acne cosmetics. 
However, patients often sought information and advices from healthcare profession-
als such as general practitioners, dermatologists or pharmacists.
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Objectives: Although chronic spontaneous (idiopathic) urticaria (CSU/CIU) is not 
life threatening, it can significantly impact a patient’s life when not adequately 
controlled by medication. Patients experience disturbing itch, intermittent pain, lack 
of sleep, occupational disabilities and social isolation with high impact on health-
related quality of life (HRQoL). However, data on the humanistic burden associated 
with symptomatic persistent CSU/CIU is scarce. Here we present data on utility 
values from the first international burden of illness study in CSU/CIU. MethOds: 
ASSURE-CSU is an observational, non-interventional study which included a 1-year 
retrospective medical record abstraction and a cross-sectional patient-reported out-
comes survey. Adult CSU/CIU patients aged > 18 years with disease persisting for ≥ 12 
months despite treatment were assessed. Utility values and domain scores from 
EQ-5D-3L were described for Canada, Germany, UK and the Netherlands. Results: 
A total of 88, 98, 79 and 99 patients completed the patient survey which included 
the EQ-5D-3L in Canada, Germany, UK and the Netherlands, respectively. The mean 
(SD) EQ-5D-3L utility score was 0.71 (0.30) for Canada; 0.71 (0.25) for Germany; 0.72 
(0.31) for UK and 0.76 (0.27) for the Netherlands. Among the different dimensions 
of EQ-5D-3L, pain/discomfort was the most affected with 62.0%, 70.5%, 61.5% and 
56.6% of patients reporting moderate to extreme problems, respectively. The second 
most affected dimension was anxiety/depression for Canada, Germany and UK with 
41.8%, 51.6% and 45.6% of patients reporting moderate to extreme problems, respec-
tively. For the Netherlands, usual activities (44.4%) was the second most affected 
dimension. Impact across all dimensions increased with disease severity and cor-
respondingly utility values decreased. cOnclusiOns: This is the first real-world 
study to assess utility values in CSU/CIU using EQ-5D. Utility scores were similar 
among the countries and ranged from 0.71 to 0.76, suggesting that CSU/CIU have 
significant impact on the patients’ health status. Pain/discomfort was the most 
affected dimension across countries.
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Objectives: To evaluate disease burden, clinical and patient-reported outcomes 
and healthcare costs of patients admitted to hospital for management of plaque 
or erythrodermic psoriasis. MethOds: This observational study enrolled 61 eligible 
patients from 107 hospital stays across 9 UK hospitals. Sites recorded Psoriasis Area 
Severity Index (PASI) at admission and discharge, psoriasis treatments, and length 
of stay (LOS). Patients reported psoriasis-related symptoms, health status (SF-12v2, 
EQ-5D-3L), mood (HADS), productivity (WPAI), and dermatology-related quality of life 
(DLQI) at admission, and also reported psoriasis-related symptoms, EQ-5D-3L, and 
DLQI at discharge. An algorithm assigned cost/hospital stay. Descriptive statistics 
are based on those responding to each item. Statistical significance evaluated at the 
0.05 level. Results: Mean age was 45.5 years; 50.8% were male. Mean time since 
psoriasis diagnosis was 20.0 years. Most (78.7%) had ≥ 1 previous psoriasis-related 
hospitalization. Mean number of physician-diagnosed co-morbid conditions was 2.5. 
At admission, mean SF-12v2 Physical and Mental component summary scores were 
35.4 and 32.1, respectively; mean HADS scores were 9.7 (anxiety) and 9.6 (depres-
sion) indicating substantial impairment. Forty-five percent reported changing job, 
role, or position at work due to psoriasis. Mean WPAI activity impairment at admis-
sion was 68.7%; among the 35.1% employed for pay, mean WPAI work impairment 
was 79.2%. Mean PASI improved from admission to discharge (25.2→ 12.1; p< 0.0001). 
Also, improvement was seen at discharge for EQ-5D-3L (0.34 → 0.60), DLQI total score 
(20.1→ 12.0), and psoriasis symptom scores (all p< 0.05). Mean (range) LOS was 17.0 
(2,71) days; for 8 patients achieving a 75% reduction in PASI (PASI75), mean LOS was 
18.1 vs. 13.1 days for 27 patients not achieving PASI75 (p= 0. 11). Mean (SD) cost/hos-
pital stay was £4,875 (±£3,096). cOnclusiOns: Disease burden, LOS and cost are 
substantial among patients hospitalized for psoriasis. On average, patients improved 
during their hospital stay. Nonetheless, they reported suboptimal clinical and patient-
reported outcomes at discharge.
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total of 731 participants had the inclusion criteria, mean age was 45 years old 
(SD= 6.3). Seventy six percent (n= 490) reported being affected of a skin psoria-
sis, 1.64% (n= 12) by psoriatic arthritis, and 31.33% (n= 229) by both types. Items 
causing higher social impact were those related to personal exposure in public 
places (scale 0-10: 6.08) and participation in sport activities (scale 0-10: 5.68); Less 
than half of participants reported managing these two issues successfully. Social 
impact of psoriasis was higher in younger participants, living alone, or not mar-
ried, unemployed, and with less household income (p< 0,001). cOnclusiOns: 
Impact of psoriasis might be assessed and requires clinical, social actions and 
emotional support to ensure patients with psoriasis having the best care. Specific 
population groups need specific health care interventions to avoid harms of social-
ization linked to psoriasis.
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Objectives: To examine the association between inflammation reduction and 
visual function response in subjects with active NIU of the posterior segment who 
received intravitreal sirolimus in SAKURA Study 1, a phase 3, double-masked, 
multinational study. MethOds: Visual function was assessed via best corrected 
visual acuity (BCVA) and the National Eye Institute Visual Function Questionnaire 
(NEI-VFQ-25). Principal component analysis was used to identify 3 visual func-
tion measures. Minimal clinically important differences (MCID) for the VFQ-25 
Composite and VFQ-25 Mental Health subscale scores were established based on 
the standard error of measurements of baseline scores. For BCVA, 2 ETDRS lines of 
improvement was used as a meaningful threshold. Response on any single meas-
ure was considered an overall visual function response. Anatomic vitreous haze 
(VH) response was defined as a VH score of 0 or 0.5+ at Month 5. Results: 347 sub-
jects were randomized 1:1:1 to every-other-month injections of intravitreal siroli-
mus 44 µg (active control), 440 µg, or 880 µg. Significantly more subjects in the 440 
µg group (52.6%) achieved an anatomic response compared with the 44 µg group 
(35.0%) (p= .008). When the MCID for the NEI-VFQ-25 Composite and Mental Health 
subscale scores were established at 4.3 and 11.7 points, respectively, the associa-
tion between anatomic and visual function response was statistically significant. 
In those achieving an anatomic response, a significant relationship was seen 
with all visual function response measures: VFQ-25 Composite score (OR= 2.234; 
p= .0004); VFQ-25 Mental Health subscale score (OR= 2.837; p< .0001); BCVA 2-line 
improvement (OR= 2.601; p= .0009), and overall visual function response (OR= 2.650; 
p< .0001). cOnclusiOns: In SAKURA Study 1, the reduction of inflammation to a 
VH score of 0 or 0.5+ was significantly associated with improved visual function as 
measured by BCVA, VFQ-25 Composite, VFQ-25 Mental Health, and overall visual 
function responses. Thus, achieving a VH response of 0 or 0.5+ can be considered 
a patient-relevant outcome.
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Objectives: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show improve-
ments in health-related quality of life (HRQoL). Glaucoma is a chronic disease 
with high importance for patient HRQoL. The objective of this study was to review, 
analyze, and understand trends in the PRO instruments used in patients with 
Glaucoma. MethOds: A systematic literature search for Glaucoma trials with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google 
Scholar and Cochrane. Data was collected for the study size, interventions, year, 
PRO instrument and Resultsfor PROs. Analysis for conducted to identify trends 
in commonly used PRO instruments and categorize Resultsas positive, neutral 
or negative. Results: 31 studies with a total of 9819 patients were identified. In 
these studies there were eleven different PROs instruments were identified that 
were Glaucoma health perception index, Glaucoma quality of life questionnaire 
(Glau-QoL), Glaucoma utility index, Impact of vision impairment, Low vision qual-
ity of life questionnaire, National eye institute visual function index-19 items, 
National eye institute visual function index-51 items, Nursing home vision quality 
of life questionnaire, Quality of life and visual function questionnaire, Vision core 
module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). cOnclusiOns: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to generate 
evidence to show which therapies improve patient QoL.
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Objectives: Infantile hemangioma (IH) is a benign neoplasm, resulting from 
vascular proliferation, with an estimated incidence of 3 to 10% within the 
first year of birth. While, in most cases, IH involute spontaneously by the age 
of 7 years, some hemangiomas (i.e. life or function-threatening IH, risk of 
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Objectives: Alexithymia is the inability to describe and project emotions in the self. 
Our objective was to assess the association between alexithymia in psoriasis (PSO) 
and loss of work productivity and activity in PSO patients. MethOds: EPIDEPSO 
(NCT01964443) is a 12-month observational, international study, to investigate 
alexithymia and other psychosocial comorbidities in PSO with disease duration 
≤ 10 years. Presence of alexithymia was defined as a score of ≥ 61 on the 20-item 
Toronto Alexithymia Scale. Work productivity and activity were assessed using the 
Work Productivity and Activity Impairment Questionnaire: PSO (WPAI-PSO). Clinical 
assessments and patient-reported outcomes included the Psoriasis Area and Severity 
Index (PASI) and the Dermatology Life Quality Index (DLQI). Results: The data dis-
played are from baseline analyses. The prevalence of alexithymia was 39% (95% CI 
35−43%). Alexithymic patients had higher unemployment rates than non-alexithymic 
patients (48% vs 25%, p< 0.0001). WPAI-PSO Resultsamong employed patients showed 
comparable absenteeism between alexithymic and non-alexithymic patients, but 
more impairment at work (presenteeism) (29% vs 13%) and productivity loss (34% vs 
17%) was greater in alexithymic than non-alexithymic patients. In both employed 
and unemployed patients there was greater activity impairment among alexithymic 
patients (38% vs 20%, all p< 0.0001). In the overall population, patients with a PASI 
score > 10 showed more impairment at work (24% vs 15%), greater productivity loss 
(30% vs 18%) and greater activity impairment (36% vs 20%) than those with a PASI 
score ≤ 10 (all p< 0.01). Moderate correlations between DLQI and presenteeism (r= 0.56), 
productivity loss (r= 0.55) and activity impairment (r= 0.65, all p-values < 0.0001) were 
identified. cOnclusiOns: In PSO patients, the inability to describe and project emo-
tions may have an impact on daily work productivity and activity. Our data indicate 
that there is a complex relationship between alexithymia, disease severity, and quality 
of life upon employment status and productivity.
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Objectives: To validate the Spanish version of the UAS, the most widely used 
patient-reported outcome measure for patients with chronic idiopathic urti-
caria (CIU), and its administration over 7 consecutive days (UAS7). MethOds: 
Observational, prospective, multicentre study in adult patients with CIU. The UAS 
has 2 items (intensity of pruritus and number of hives, scored 0-3) and ranges from 
0-6 (lowest to highest disease activity). The UAS7 is the sum of UAS over 7 consecu-
tive days. Both scales were completed at baseline and after 6 weeks, together with 
health-related quality of life (CU-Q2oL and EQ-5D) and disease severity (Clinician 
(CRS) and Patient Rating Scale (PRS); Clinician (CRSC) and Patient Rating Scale of 
Change (PRSC)) questionnaires. Results: 166 patients were included. Overall, 
< 16% of responses were missing or non-valid. Maximum floor and ceiling effects 
were 19.3% and 6.0%, respectively. Internal consistency was good (Cronbach’s 
alpha:UAS= 0.68 [baseline] and 0.83 [6 weeks]; UAS7= 0.83 in both visits) and test-
retest reliability was adequate (intraclass correlation coefficients of 0.65 (UAS) and 
0.84 (UAS7) in stable patients (n= 37 and 49, respectively)). Known-groups valid-
ity was supported by significantly different scores between severity subgroups 
according to CRS and PRS (P< 0.001 in all cases). Good construct validity was also 
observed, with moderate/strong correlations with the CU-Q2oL scores (r= 0.37-0.59), 
and weak correlations with the EQ-5D visual analogue scale (r= −0.15-(−0.30)) and 
index (r= −0.15-(−0.28)). Sensitivity to change was good, with large effect sizes (≥ 0.8) 
for patients with ≥ 3 points-change in severity (CRSC or PRSC). The minimally impor-
tant difference for the UAS7 ranged from 4-5, less than reported for the English 
version (9.5-10.5). cOnclusiOns: The Spanish versions of UAS and UAS7 scales are 
valid, applicable and reliable tools to assess disease control in the clinical practice 
in patients with CIU. A 4-5 point change on the Spanish UAS7 might be interpreted 
as an important difference.
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Objectives: Psoriasis is a chronic skin disease that causes an important physical, 
psychological, and economic impact on the people affected. However social impact 
has not been studied until recently. The objective of this study was to examine 
the social impact of psoriasis as reported by patients. MethOds: Data came from 
the study “Acción 2014”, an online survey carried out by the Spanish association 
of patients and their families affected by Psoriasis and psoriatic arthritis (“Acción 
Psoriasis”), the study took place from December 2013 to April 2014. We included 
all psoriatic Spanish participants, and we examined the set of 13 items referred to 
the social impact of psoriasis using a Rasch model. This implied studying the scale 
functioning, item fit, item dependency, and the unidimensionality assumption. 
The units of the Rasch (logits) were transformed into a 0-10 scale. We analysed 
overall differences between groups of patients with ANOVA tests. Results: A 
